User profiles for Kerem Eitan

Eitan Kerem

Verified email at mail.huji.ac.il
Cited by 20094

[HTML][HTML] Prediction of mortality in patients with cystic fibrosis

E Kerem, J Reisman, M Corey, GJ Canny… - New England Journal …, 1992 - Mass Medical Soc
Background. The majority of patients with cystic fibrosis die in early adulthood of lung disease.
Lung transplantation is a treatment option for patients with advanced pulmonary disease, …

[HTML][HTML] The Relation between Genotype and Phenotype in Cystic Fibrosis — Analysis of the Most Common Mutation (ΔF508)

E Kerem, M Corey, B Kerem, J Rommens… - … England Journal of …, 1990 - Mass Medical Soc
Background and Methods. Both the clinical manifestations of cystic fibrosis and the genotypes
of patients are heterogeneous, but the associations between the two are not known. We …

The future of cystic fibrosis care: a global perspective

…, N Kashirskaya, E Kerem… - The Lancet …, 2020 - thelancet.com
The past six decades have seen remarkable improvements in health outcomes for people
with cystic fibrosis, which was once a fatal disease of infants and young children. However, …

[HTML][HTML] Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations

…, Z Bebok, L Shushi, B Kerem, E Kerem - … England Journal of …, 2003 - Mass Medical Soc
Background Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR)
gene containing a premature termination signal cause a deficiency or absence of functional …

[HTML][HTML] Standards of care for patients with cystic fibrosis: a European consensus

E Kerem, S Conway, S Elborn, H Heijerman… - Journal of cystic …, 2005 - Elsevier
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene [1, 2]. This results in dysfunction of the apical membrane CFTR …

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

E Kerem, S Hirawat, S Armoni, Y Yaakov, D Shoseyov… - The Lancet, 2008 - thelancet.com
Background In about 10% of patients worldwide and more than 50% of patients in Israel, cystic
fibrosis results from nonsense mutations (premature stop codons) in the messenger RNA (…

[HTML][HTML] Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis

…, C Daines, FC Ringshausen, E Kerem… - … England Journal of …, 2017 - Mass Medical Soc
Background Cystic fibrosis is an autosomal recessive disease caused by mutations in the
CFTR gene that lead to progressive respiratory decline. Some mutant CFTR proteins show …

Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life

…, D Shoseyov, E Kerem - American journal of …, 2011 - atsjournals.org
The survival of patients with cystic fibrosis (CF) continues to improve. The discovery and
cloning of the CFTR gene more than 21 years ago led to the identification of the structure and …

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

E Kerem, MW Konstan, K De Boeck… - The Lancet …, 2014 - thelancet.com
Background Ataluren was developed to restore functional protein production in genetic disorders
caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients…

[HTML][HTML] Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism

E Kerem, T Bistritzer, A Hanukoglu… - … England Journal of …, 1999 - Mass Medical Soc
Background Active sodium absorption is the dominant mechanism of ion transport in airway
epithelium, but its role in pulmonary physiology and airway host defense is unknown. To …